Dapagliflozin is an SGLT2 inhibitor used to treat type 2 diabetes, heart failure, and chronic kidney disease. It lowers blood sugar by causing the kidneys to excrete excess glucose in the urine and offers significant protective effects for the heart and kidneys.

Empagliflozin is an SGLT2 inhibitor that treats type 2 diabetes by helping the kidneys remove glucose from the bloodstream through urine. It is also proven to reduce the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease.